The cross-disciplinary team performing this research will examine how mobile DNA elements found in brain cells move in response to learning and memory exercises in mice, and whether these changes generate an address system for parts of the brain to be turned on by specific experiences. This work has major implications for our fundamental understanding of how the brain works in healthy individuals, as well as people affected by neurodevelopmental and neurodegenerative conditions.
Betacellulin: Defining A Novel Sub-type In Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$907,515.00
Summary
Schizophrenia is a severe lifelong mental disorder affecting 0.7% of the world population with only partially effective symptomatic treatments. Its cause is unknown and thus cures cannot be developed currently. A promising candidate is betacellulin a growth factor which is very reduced in the brain and blood of people with schizophrenia. Little is known about its role in the brain and this project seeks to identify its relevance to schizophrenia as a step to develop new treatments.
Mechanisms Of Ataxia In Spinocerebellar Ataxia Type 1 Transgenic Mice
Funder
National Health and Medical Research Council
Funding Amount
$361,158.00
Summary
Degeneration of the coordination part of the brain (cerebellum) causes ATAXIA. There are many types, but few can be cured. The majority, affecting ~ 3,000 Australians, are progressive, and can only be helped by physical therapies. We are searching for a drug to improve the SYMPTOMS of ataxia, by analysing the chemical transmitters in the cerebellum in genetically ataxic mice. If we find an imbalance, we will trial appropriate drugs to try to correct this and lessen ataxia.
Variation in our genetic makeup can cause serious brain disorders such as epilepsy. The goal of this research is to determine how variation in an epilepsy patients genes produce fundamental changes in brain function that lead to epilepsy. This is a multidisciplinary program that combines clinical, genetic, electrophysiological, morphological and computational approaches to create a fundamental understanding of the genesis of this important disease.
Novel Signalling Pathways Leading To The Activation Of Glomerular Parietal Epithelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
Chronic kidney disease (CKD) is a major health problem in Australia. CKD patients have very limited therapeutic options. The majority of diseases that lead to CKD are associated scarring of the renal filters. Parietal epithelial cells reside in these filters and play key roles in scarring development. However, the molecular mechanisms that lead to scarring in these renal filters remain unclear. This proposal aims to identify molecular pathways that may serve as future therapeutic targets.
Vascular Changes Are A Key Contributor To And Novel Drug Target For Interferon-alpha Induced Neurological Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,245,401.00
Summary
Type I interferons (IFN-Is) contribute to wide range of neurological diseases including ageing and neurodegeneration. At its extreme IFN-I-mediated neurodegeneration is known as 'interferonopathy'. The mechanisms of how IFN-Is drive disease are unclear, making causal treatment difficult. We have recently uncovered ground-breaking evidence that abnormal blood vessels are a key contributor to the disease. Here, we will investigate novel treatment targets for patients with interferonopathies.
Sortilin Forms A Complex With APP And BACE To Regulate Abeta Production
Funder
National Health and Medical Research Council
Funding Amount
$208,910.00
Summary
Alzheimer's disease is a neurodegenerative disorder which is highly prevalent in aging population. Amyloid beta is a toxic peptide derived from a metabolic processing of its precursor amyloid precursor protein (APP). This project will examine how a novel protein called sortilin interacts with APP and its processing enzyme and how the toxic peptide is produced. Understanding the trafficking of APP and beta-secretase ?BACE? regulated by sortilin may help understanding how Alzheimer's disease is de ....Alzheimer's disease is a neurodegenerative disorder which is highly prevalent in aging population. Amyloid beta is a toxic peptide derived from a metabolic processing of its precursor amyloid precursor protein (APP). This project will examine how a novel protein called sortilin interacts with APP and its processing enzyme and how the toxic peptide is produced. Understanding the trafficking of APP and beta-secretase ?BACE? regulated by sortilin may help understanding how Alzheimer's disease is developed.Read moreRead less
Frontotemporal Dementia And Motor Neurodegenerative Syndromes
Funder
National Health and Medical Research Council
Funding Amount
$11,583,107.00
Summary
Frontotemporal degeneration of the brain is a leading cause of morbidity. It is a pathologically heterogeneous group of rapidly-progressive disorders with behavioural, language and motor deficits. This research program brings together international leaders in clinical, pathological and biological research of these syndromes, aiming to fast track new knowledge and innovations to develop the necessary tools and therapies to effectively diagnose, manage and treat these disorders.